Comparable stake leader
Auctus Fund Management LLC
SEC ownership of GUIDED THERAPEUTICS INC
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0000924515.
Disclosed value leader
John E. Imhoff
Comparable rows
1/5
Latest evidence
10 Mar 2026
- Public ticker
- GTHP on OTC
- Parsed ownership sources
-
13D/G and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Auctus Fund Management LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
1 of 5
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Auctus Fund Management LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
10 Mar 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0000924515
- Issuer location
- Peachtree Corners, GA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of GUIDED THERAPEUTICS INC (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Auctus Fund Management LLC
Disclosed value leader
John E. Imhoff
Comparable rows
1/5
Latest evidence
10 Mar 2026
13D/G
3/4/5
Lead comparable stake: 9.9%
4 rows are not safely comparable across share classes.
13D/G row: Auctus Fund Management LLC
Quick read
Auctus Fund Management LLC leads the comparable SEC ownership view at 9.9%.
1 of 5 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Auctus Fund Management LLC's linked filing trail.
Comparable ownership
Top 1
Auctus Fund Management LLC
9.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-5 of 5 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Auctus Fund Management LLC |
13D/G
|
9.9%
|
$638,535
5,804,865 shares
|
$0 | 30 Sep 2024 |
| John E. Imhoff |
3/4/5
Director, 10%+ Owner
|
—
mixed-class rows
|
$7,368,584
21,472,673 shares
mixed-class rows
|
+$30,000 | 10 Mar 2026 |
| Richard P. Blumberg |
3/4/5
Director, 10%+ Owner
|
—
mixed-class rows
|
$1,426,352
13,201,311 shares
mixed-class rows
|
— | 25 Feb 2026 |
| Alan Grujic |
3/4/5
Director
|
—
mixed-class rows
|
$327,157
2,104,649 shares
mixed-class rows
|
— | 10 Mar 2026 |
| Michael C. James |
3/4/5
Director
|
—
mixed-class rows
|
$228,723
816,273 shares
mixed-class rows
|
+$5,000 | 10 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$35,000.
Buys
$35,000
Insiders: 2
Sells
$0
Insiders: 0
Net
+$35,000
Shares: +194,445
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 194,445
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 194,445 | 0 | $35,000 | $0 | +$35,000 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-4 of 4 reporting-owner rows connected to GUIDED THERAPEUTICS INC. Open a relationship link for the CIK-to-CIK filing trail.
Rows
4
Largest Forms 3/4/5 holder
John E. Imhoff
Net 12M change
+$35,000
Latest report
10 Mar 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| John E. Imhoff | Director, 10%+ Owner | $7,368,584 | +$30,000 | +0.41% | Mixed | 10 Mar 2026 |
| Richard P. Blumberg | Director, 10%+ Owner | $1,426,352 | Mixed | 25 Feb 2026 | ||
| Alan Grujic | Director | $327,157 | Filing P/S | 10 Mar 2026 | ||
| Michael C. James | Director | $228,723 | +$5,000 | +2.2% | Mixed | 10 Mar 2026 |
Recent insider transactions for GUIDED THERAPEUTICS INC
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| John E. Imhoff | GTHP | Common Stock | Conversion of derivative security | 0.75% | 157,417 | 21,252,673 | 31 Mar 2026 | Direct | ||
| John E. Imhoff | GTHP | Convertible Promissory Note | Conversion of derivative security | -58.9% | -157,417 | 110,000 | 31 Mar 2026 | Direct | ||
| Richard P. Blumberg | GTHP | Preferred Series F-2 Stock | Other | -100% | -88 | 0 | 26 Mar 2026 | Direct | ||
| Richard P. Blumberg | GTHP | Preferred Series F Stock | Other | -100% | -260 | 0 | 26 Mar 2026 | Direct | ||
| Richard P. Blumberg | GTHP | Common Stock | Other | 16.4% | 1,467,131 | 10,391,311 | 26 Mar 2026 | Direct | ||
| John E. Imhoff | GTHP | Preferred Series F Stock | Other | -100% | -10 | 0 | 26 Mar 2026 | Direct | ||
| John E. Imhoff | GTHP | Common Stock | Other | 0.2% | 42,157 | 21,095,256 | 26 Mar 2026 | Direct | ||
| Richard P. Blumberg | GTHP | Stock Options | Award | 110,000 | 110,000 | 10 Mar 2026 | Direct | |||
| Alan Grujic | GTHP | Stock Options | Award | 110,000 | 110,000 | 10 Mar 2026 | Direct | |||
| John E. Imhoff | GTHP | Stock Options | Award | 110,000 | 110,000 | 10 Mar 2026 | Direct | |||
| Michael C. James | GTHP | Stock Options | Award | 110,000 | 110,000 | 10 Mar 2026 | Direct | |||
| Richard P. Blumberg | GTHP | Warrants | Expiration (or cancellation) of long derivative position with value received | -25% | -900,000 | 2,700,000 | 01 Mar 2026 | Direct | ||
| John E. Imhoff | GTHP | Common Stock | Conversion of derivative security | 0.75% | 156,086 | 21,053,099 | 27 Feb 2026 | Direct | ||
| John E. Imhoff | GTHP | Common Stock | Other | 1.95% | 400,000 | 20,897,013 | 27 Feb 2026 | Direct | ||
| John E. Imhoff | GTHP | Preferred Series E Stock | Other | -100% | -100 | 0 | 27 Feb 2026 | Direct | ||
| John E. Imhoff | GTHP | Convertible Promissory Note | Conversion of derivative security | -56.5% | -156,086 | 120,000 | 27 Feb 2026 | Direct | ||
| Richard P. Blumberg | GTHP | Common Stock | Options Exercise | 12.6% | 1,000,000 | 8,924,180 | 25 Feb 2026 | Direct | ||
| Richard P. Blumberg | GTHP | Warrants | Options Exercise | -100% | -1,000,000 | 0 | 25 Feb 2026 | Direct | ||
| Richard P. Blumberg | GTHP | Warrants | Award | 1,000,000 | 1,000,000 | 25 Feb 2026 | Direct | |||
| Richard P. Blumberg | GTHP | Warrants | Disposed to Issuer | -100% | -1,000,000 | 0 | 25 Feb 2026 | Direct | ||
| John E. Imhoff | GTHP | Common Stock | Exercise of in-the-money or at-the-money derivative security | 2.5% | 500,000 | 20,497,013 | 25 Feb 2026 | Direct | ||
| John E. Imhoff | GTHP | Warrants | Exercise of in-the-money or at-the-money derivative security | -100% | -500,000 | 0 | 25 Feb 2026 | Direct | ||
| John E. Imhoff | GTHP | Warrants | Other | 1,000,000 | 500,000 | 25 Feb 2026 | Direct | |||
| John E. Imhoff | GTHP | Warrants | Other | -100% | -1,000,000 | 0 | 25 Feb 2026 | Direct | ||
| Michael C. James | GTHP | Common Stock | Exercise of in-the-money or at-the-money derivative security | 18.1% | 100,000 | 653,495 | 25 Feb 2026 | Direct | ||
| Michael C. James | GTHP | Warrants | Exercise of in-the-money or at-the-money derivative security | -65.4% | -100,000 | 52,778 | 25 Feb 2026 | Direct | ||
| Michael C. James | GTHP | Warrants | Other | 200,000 | 152,778 | 25 Feb 2026 | Direct | |||
| Michael C. James | GTHP | Warrants | Other | -100% | -200,000 | 0 | 25 Feb 2026 | Direct | ||
| John E. Imhoff | GTHP | Common Stock | Conversion of derivative security | 1.59% | 312,720 | 19,997,013 | 02 Feb 2026 | Direct | ||
| John E. Imhoff | GTHP | Convertible Promissory Note | Conversion of derivative security | -70.6% | -312,720 | 130,000 | 02 Feb 2026 | Direct | ||
| John E. Imhoff | GTHP | Common Stock | Other | 0.13% | 25,338 | 19,684,293 | 05 Jan 2026 | Direct | ||
| John E. Imhoff | GTHP | Common Stock | Conversion of derivative security | 1% | 195,460 | 19,658,955 | 18 Dec 2025 | Direct | ||
| John E. Imhoff | GTHP | Convertible Promissory Note | Conversion of derivative security | -56.6% | -195,460 | 150,000 | 18 Dec 2025 | Direct | ||
| Alan Grujic | GTHP | Common Stock | Purchase | 9.13% | 152,108 | 1,817,541 | 29 Aug 2025 | Direct | ||
| Alan Grujic | GTHP | Warrants | Purchase | 608.4% | 152,108 | 177,108 | 29 Aug 2025 | Direct | ||
| John E. Imhoff | GTHP | Common Stock | Purchase | 0.86% | $30,000 | $0.1800 | 166,667 | 19,463,495 | 29 Aug 2025 | Direct |
| John E. Imhoff | GTHP | Warrants | Purchase | 666.7% | 166,667 | 191,667 | 29 Aug 2025 | Direct | ||
| Michael C. James | GTHP | Common Stock | Purchase | 5.28% | $5,000 | $0.1800 | 27,778 | 553,495 | 29 Aug 2025 | Direct |
| Michael C. James | GTHP | Warrants | Purchase | 111.1% | 27,778 | 52,778 | 29 Aug 2025 | Direct | ||
| Alan Grujic | GTHP | Preferred Series E Stock | Other | -100% | -50 | 0 | 21 Aug 2025 | Direct | ||
| Alan Grujic | GTHP | Common Stock | Other | 15% | 217,408 | 1,665,433 | 21 Aug 2025 | Direct | ||
| John E. Imhoff | GTHP | Preferred Series E Stock | Other | -75% | -300 | 100 | 21 Aug 2025 | Direct | ||
| John E. Imhoff | GTHP | Common Stock | Other | 7.25% | 1,304,448 | 19,296,828 | 21 Aug 2025 | Direct | ||
| Richard P. Blumberg | GTHP | Preferred Series E Stock | Other | -100% | -233 | 0 | 21 Aug 2025 | Direct | ||
| Richard P. Blumberg | GTHP | Common Stock | Other | 14.7% | 1,013,121 | 7,924,180 | 21 Aug 2025 | Direct |
* marks a reported price that did not pass the local price check.